Claims for Patent: 8,314,066

Summary for Patent: 8,314,066

Title:	GH secretagogues and uses thereof
Abstract:	The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
Inventor(s):	Abribat; Thierry (St-Foy-les-Lyon, FR), De Villers; Andre (Outremont, CA), Chapdelaine; Alcide (Ile des Soeurs, CA), Allas; Soraya (Iles des Soeurs, CA), Gravel; Denis (Saint-Lambert, CA)
Assignee:	Theratechnologies Inc. (Montreal, Quebec, CA)
Application Number:	11/877,395
Patent Claims:	1. A method of treating HIV-related lipodystrophy in a subject without significantly impairing glucose control, said method comprising administering to said subject (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) to treat said HIV-related lipodystrophy without significantly impairing glucose control. 2. The method of claim 1, wherein said subject is receiving antiviral therapy. 3. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered at a dose selected from the group consisting of about 1 mg and about 2 mg. 4. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered by a route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal and topical. 5. The method of claim 4, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered by a subcutaneous route. 6. The method of claim 3, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered at a dose of about 2 mg. 7. The method of claim 5, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered at a dose selected from the group consisting of about 1 mg and about 2 mg. 8. The method of claim 7, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 (SEQ ID NO: 7) is administered at a dose of about 2 mg. 9. The method of claim 1, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation. 10. The method of claim 2, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation. 11. The method of claim 3, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation. 12. The method of claim 4, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation. 13. The method of claim 5, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation. 14. The method of claim 6, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation. 15. The method of claim 7, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation. 16. The method of claim 8, wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation. 17. The method of claim 1, wherein said subject further suffers from type II diabetes or glucose intolerance. 18. The method of claim 2, wherein said subject further suffers from type II diabetes or glucose intolerance. 19. The method of claim 3, wherein said subject further suffers from type II diabetes or glucose intolerance. 20. The method of claim 4, wherein said subject further suffers from type II diabetes or glucose intolerance. 21. The method of claim 5, wherein said subject further suffers from type II diabetes or glucose intolerance. 22. The method of claim 6, wherein said subject further suffers from type II diabetes or glucose intolerance. 23. The method of claim 7, wherein said subject further suffers from type II diabetes or glucose intolerance. 24. The method of claim 8, wherein said subject further suffers from type II diabetes or glucose intolerance. 25. The method of claim 9, wherein said subject further suffers from type II diabetes or glucose intolerance.